Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33527596 | 0.80 | KEAP1 (0.33) | KEAP1NFE2L2 | |
| SCHEMBL33527615 | 0.72 | PDE2A (0.36) | PDE2APDE10ACCR4 | |
| SCHEMBL33526226 | 0.71 | KDM4E (0.35) | GRM4PDE2APDE10A | |
| SCHEMBL22824045 | 0.69 | KEAP1 (0.35) | KEAP1NFE2L2HRH4 | |
| SCHEMBL29365609 | 0.69 | KEAP1 (0.35) | KEAP1NFE2L2HRH4 | |
| SCHEMBL33526945 | 0.69 | S100B (0.34) | PDE2APDE10A | |
| SCHEMBL33525628 | 0.68 | — | — | |
| SCHEMBL12090788 | 0.64 | PIK3CA (0.34) | CCR4HRH4 | |
| SCHEMBL20719582 | 0.64 | ALDH1A1 (0.42) | KEAP1NFE2L2 | |
| SCHEMBL33526256 | 0.64 | MAOB (0.36) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | GRM4 445/4885PDE2A 995/4885PDE10A 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.